<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910521-0033</DOCNO><DOCID>910521-0033.</DOCID><HL>   Technology Brief -- Schering-Plough Corp.:   EC Committee Gives Nod   On Drug for Hepatitis C</HL><DATE>05/21/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   BGEN SGP</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DRUG MANUFACTURERS (DRG)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><RE>EUROPEAN COMMUNITY (EC)MASSACHUSETTS (MA)NEW JERSEY (NJ)</RE><LP>   Schering-Plough Corp., Madison, N.J., said a EuropeanCommunity committee recommended approval of Intron A, analpha interferon, to treat a chronic, sometimes fatal form ofhepatitis.   Schering-Plough, which makes and markets the drug underlicense with Biogen Inc., Cambridge, Mass., said that in ECcountries, about 240,000 people each year become acutelyinfected with a form of hepatitis known as hepatitis C. Ofthose, about 50% develop the chronic form of the disease.Intron A is the trade name for a genetically engineered copyof a human protein that acts as an antiviral agent. It isalready on the market to treat chronic hepatitis B in some ECnations.</LP><TEXT>   The preliminary approval in the EC by the Committee forProprietary Medicinal Products suggests the drug will soon bemore widely available in the EC. Three EC countries hadpreviously approved the product for hepatitis C.   World-wide sales of Intron A totaled $177 million in 1990.</TEXT></DOC>